A new study reveals that extended use of common acid reflux medications may significantly increase the likelihood of developing dementia — and millions of patients may be unaware.
The Common Drug at the Center of a Troubling Discovery
Proton pump inhibitors, among the most widely used medications in the world, are coming under renewed scientific scrutiny. A large-scale study published in the journal Neurology found that people who use these acid reflux drugs for more than four and a half years face a 33 percent higher risk of developing dementia compared to those who never took them. For the millions of people who rely on these medications daily, the findings raise urgent and uncomfortable questions.
Acid reflux, a condition in which stomach acid travels up into the esophagus, affects a significant portion of the population — in the United Kingdom alone, up to 40 percent of people experience it regularly. For those with severe or persistent cases, gastroesophageal reflux disease, or GERD, can develop, sometimes leading to esophageal cancer. Proton pump inhibitors, or PPIs, are a cornerstone treatment, reducing stomach acid by blocking the enzymes in the stomach lining responsible for producing it. The drugs are regarded as safe and effective for short-term use.
What the Research Found About Proton Pump Inhibitors
The American research team examined data from more than 5,700 adults aged 45 and older who showed no signs of dementia at the start of the study. With an average participant age of 75, researchers tracked medication use through study visits and annual phone calls. Roughly 26 percent of participants — about 1,490 people — had used PPIs at some point.
Participants were grouped based on duration of use: those who never took the drugs, those who took them for fewer than 2.8 years, those who took them between 2.8 and 4.4 years, and those who used them for more than 4.4 years. Over an average follow-up period of approximately five and a half years, 585 participants developed dementia, representing about 10 percent of the total group.
Among the 4,222 people who never took PPIs, 415 developed dementia — roughly 19 cases per 1,000 person-years. By contrast, among the 497 long-term users, 58 developed the condition — equivalent to approximately 24 cases per 1,000 person-years. After controlling for variables including age, sex, race, high blood pressure and diabetes, the researchers calculated a statistically significant 33 percent elevated risk for those with prolonged use.
Crucially, the elevated risk was exclusive to long-term users. No increased dementia risk was observed among those who took PPIs for fewer than 4.4 years.
What Scientists Say About the Findings
The study’s lead author, vascular neurologist Professor Kamakshi Lakshminarayan of the University of Minnesota School of Public Health, was measured in her interpretation of the findings. The research, she emphasized, does not establish that these drugs cause dementia — only that an association exists between extended use and heightened risk.
Previous studies have connected long-term PPI use to other health concerns, including increased risk of stroke, bone fractures and chronic kidney disease. Whether the drugs independently accelerate cognitive decline, or whether prolonged use reflects underlying health patterns that elevate dementia risk, remains an open question requiring further investigation.
Lakshminarayan acknowledged that alternative approaches to managing acid reflux exist — including antacids, weight management, and dietary adjustments — but noted that no single solution works for everyone.
A Cautious Path Forward for Patients
Perhaps the most important takeaway from the study is what patients should not do: stop their medication abruptly. Sudden discontinuation of PPIs can trigger a rebound effect, causing symptoms to worsen significantly. Medical professionals advise that any changes to a PPI regimen should be made in consultation with a physician, who can evaluate the best course of action based on an individual’s complete medical history and risk profile.
The study adds to a growing body of literature calling for more targeted prescribing of PPIs — particularly for patients who may not need long-term treatment. For those who do, regular reassessment with a healthcare provider is increasingly recommended. As the scientific community continues to examine the potential cognitive trade-offs of these widely prescribed drugs, patients are best served not by alarm, but by informed, ongoing conversation with their doctors.
Source: Mirror